Medication info
SMFRA Tablet 40mg (Esomeprazole Magnesium Trihydrate)

SMFRA Tablet 40mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Dihydrate›43.38mg / 1 tablet
Manufacturer / importer
Huons Co., Ltd.
Appearance
Pink, rectangular film-coated tablets
Packaging
14 tablets (7 tablets/ Alu-Alu x 2)
Approval status
Active

MFDS item code 201507270 · Approved 2015.10.21 · Insurance code 670607310

Summary

Main use
Treatment of acid-related disorders (reflux, Zollinger-Ellison syndrome), ulcers and H. pylori eradication, and gastrointestinal disorders caused by anti-inflammatory analgesics
Who uses it
Adults · Children
Adult dosage
This medication should be swallowed with a liquid such as water; do not chew or crush it. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue taking it for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this medication 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug use (COX-2 nonselective or selective) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. Clinical trials lasting longer than 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug therapy - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The subsequent dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided and taken twice daily. 6) Maintenance therapy following initiation of prevention of rebleeding due to gastric or duodenal ulcers by intravenous injection Administer 40 mg once daily for 4 weeks following initiation of prevention of rebleeding due to gastric or duodenal ulcers by intravenous injection. 4. Renal impairment No dose adjustment is necessary. Use with caution because there is limited experience with administration to patients with severe renal impairment. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medication must not exceed 20 mg. 6. Older adults No dose adjustment is necessary.
Children's dosage
Adolescents aged 12 years and older — 1) Gastroesophageal reflux disease (GERD): Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue taking it for an additional 4 weeks. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. Adolescents aged 12 years and older — Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. Adolescents aged 12 years and older — In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Children under 12 years of age — There is no experience with administration of this medication to children under 12 years of age.

Ingredients

Manufacturer
Huons Co., Ltd.

Efficacy & effects

Treatment of acid-related disorders (reflux, Zollinger-Ellison syndrome), ulcers and H. pylori eradication, and gastrointestinal disorders caused by anti-inflammatory analgesics

  • Gastroesophageal reflux disease
  • erosive reflux esophagitis
  • esophagitis
  • duodenal ulcer positive for Helicobacter pylori
  • peptic ulcer
  • upper gastrointestinal pain
  • discomfort
  • burning sensation in the upper gastrointestinal tract
  • gastric ulcer related to nonsteroidal anti-inflammatory drugs
  • duodenal ulcer
  • Zollinger-Ellison syndrome
  • gastric ulcer
View approved original text

This medication is used for long-term maintenance therapy to treat and prevent recurrence of gastroesophageal reflux disease. It is also effective for the treatment and prevention of duodenal ulcer and peptic ulcer caused by Helicobacter pylori infection. Additionally, it is used for the short-term treatment associated with upper gastrointestinal symptoms caused by the use of nonsteroidal anti-inflammatory drugs and for the treatment and prevention of gastric ulcers. It is also used in the treatment of Zollinger-Ellison syndrome and the maintenance therapy after prevention of rebleeding from gastric ulcers. This medication is helpful for various gastrointestinal diseases.

Dosage and Administration

Adult dosage

This medication should be swallowed with a liquid such as water; do not chew or crush it. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue taking it for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this medication 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug use (COX-2 nonselective or selective) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. Clinical trials lasting longer than 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug therapy - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The subsequent dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided and taken twice daily. 6) Maintenance therapy following initiation of prevention of rebleeding due to gastric or duodenal ulcers by intravenous injection Administer 40 mg once daily for 4 weeks following initiation of prevention of rebleeding due to gastric or duodenal ulcers by intravenous injection. 4. Renal impairment No dose adjustment is necessary. Use with caution because there is limited experience with administration to patients with severe renal impairment. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medication must not exceed 20 mg. 6. Older adults No dose adjustment is necessary.

Children's dosage

Adolescents aged 12 years and older — 1) Gastroesophageal reflux disease (GERD): Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue taking it for an additional 4 weeks. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. Adolescents aged 12 years and older — Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. Adolescents aged 12 years and older — In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Children under 12 years of age — There is no experience with administration of this medication to children under 12 years of age.

Precautions

This medicine should not be used in certain patients. For example, patients with allergies to this drug, its ingredients, or benzimidazole class drugs, or those who have previously had such reactions should not take this medicine. Also, it should not be administered in combination with amoxicillin or clarithromycin for Helicobacter pylori eradication therapy if there is an allergy to these antibiotics. Patients with specific heart conditions or those who are breastfeeding should not use this medication. During the use of this medication, various adverse reactions may occur, including gastrointestinal symptoms such as headache, abdominal pain, diarrhea, nausea, and vomiting, as well as skin rash, itching, and rarely severe hypersensitivity reactions or blood abnormalities. Long-term use may cause electrolyte abnormalities such as hypomagnesemia, so regular monitoring is necessary. Furthermore, this drug can interact with other medications, so if you are taking other medications, you must inform your doctor or pharmacist. Caution is especially needed when used with antiviral agents, antibiotics, or blood coagulation inhibitors. The safety of this medication during pregnancy has not been fully established, so pregnant women should consult a doctor before taking it. If breastfeeding, it is advisable not to take this medicine as it may be excreted in breast milk. In case of overdose, there is no specific antidote, so it is important to receive treatment based on symptoms, and it should be stored out of reach of children.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucination, headache, dizziness, paresthesia, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, jaundice, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, skin and mucous membrane syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, Riehl's syndrome, acute generalized pustular eruption, eosinophilia, drug reactions accompanied by systemic symptoms, fractures, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile associated diarrhea, abdominal distention, allergic reaction, back pain, chest pain, substernal pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, malaise, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, thyroid gland enlargement, irritable bowel syndrome, exacerbation of constipation, dyspepsia, dysphagia, gastrointestinal malformation, epigastric pain, belching, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, oropharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue edema, ulcerative stomatitis, vomiting, earache, tinnitus, anemia, hypochromic anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver function abnormalities, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, rheumatoid polymyalgia, arthralgia, appetite loss, apathy, increased appetite, confusion, worsening depression, hypertonia, sensory loss, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorders, tremors, visual field defects, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, abnormal olfaction, loss of taste, taste distortion, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, urination frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps, nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, discoid lupus erythematosus, gastric fundic gland polyps, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a sealed container. Furthermore, it is important to maintain a cool room temperature between 1 to 30 degrees Celsius when storing the medication. This will help maintain the efficacy and safety of the medication for a long time.

Appearance and packaging

Appearance

Pink, rectangular film-coated tablets

Package unit

14 tablets (7 tablets/ Alu-Alu x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.